ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) Free cash flow
ResMed Inc.'s free cash flow for fiscal 2026 was $1.6B, unchanged from fiscal 2025. Over the past ten years it has ranged from $195.1M (fiscal 2022) to $1.7B (fiscal 2025); the current reading is higher than 92% of that period. ResMed Inc. ranks 4th of 55 Medical Instruments & Supplies companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2026 | $1.6B | (1.35%) |
| FY2025 | $1.7B | 28.34% |
| FY2024 | $1.3B | 130.00% |
| FY2023 | $559.3M | 186.66% |
| FY2022 | $195.1M | (68.53%) |
| FY2021 | $619.9M | (10.98%) |
| FY2020 | $696.3M | 82.42% |
| FY2019 | $381.7M | (11.96%) |
| FY2018 | $433.6M | 26.56% |
| FY2017 | $342.6M | (28.65%) |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $397.4M | (22.77%) |
| Mar 2026 | $514.5M | 68.60% |
| Dec 2025 | $305.2M | (25.84%) |
| Sep 2025 | $411.5M | (18.50%) |
| 42 more quarters | Free account |
Against its own ten years
Low $195.1M
High $1.7B
Ten-year median
$519.7M
Current reading's percentile
92
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BDX Becton, Dickinson and Company compare | $3.2B |
| MDLN Medline Inc. compare | $2.3B |
| RMD ResMed Inc. | $1.6B |
| ALC Alcon compare | $1.6B |
| BAX Baxter International Inc. compare | $815.0M |
| COO The Cooper Companies, Inc. compare | $678.0M |
| WST West Pharmaceutical Services, Inc. compare | $436.9M |
| RGEN Repligen Corporation compare | $110.3M |
| SOLV Solventum Corporation compare | −$118.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on RMD
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement